SI1592971T1 - Postopek za in vitro ovrednotenje stanja napredovanja okuĹľbe z virusom HIV pri posamezniku - Google Patents

Postopek za in vitro ovrednotenje stanja napredovanja okuĹľbe z virusom HIV pri posamezniku

Info

Publication number
SI1592971T1
SI1592971T1 SI200432107T SI200432107T SI1592971T1 SI 1592971 T1 SI1592971 T1 SI 1592971T1 SI 200432107 T SI200432107 T SI 200432107T SI 200432107 T SI200432107 T SI 200432107T SI 1592971 T1 SI1592971 T1 SI 1592971T1
Authority
SI
Slovenia
Prior art keywords
infection
individual
hiv virus
vitro assessment
progression status
Prior art date
Application number
SI200432107T
Other languages
English (en)
Inventor
Vincent Vieillard
Patrice Debre
Original Assignee
Institut National De La Sante Et De La Recherche Medicale(Inserm)
Assistance Publique, Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale(Inserm), Assistance Publique, Hopitaux De Paris filed Critical Institut National De La Sante Et De La Recherche Medicale(Inserm)
Publication of SI1592971T1 publication Critical patent/SI1592971T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1468—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle
    • G01N2015/1472—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle with colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486—Counting the particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200432107T 2003-02-06 2004-02-06 Postopek za in vitro ovrednotenje stanja napredovanja okuĹľbe z virusom HIV pri posamezniku SI1592971T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03290303A EP1445614A1 (en) 2003-02-06 2003-02-06 A method for the in vitro assessment of the progression status of an HIV virus in an invidual
EP04708764.8A EP1592971B1 (en) 2003-02-06 2004-02-06 A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual
PCT/EP2004/001106 WO2004070385A1 (en) 2003-02-06 2004-02-06 A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual

Publications (1)

Publication Number Publication Date
SI1592971T1 true SI1592971T1 (sl) 2013-12-31

Family

ID=32605441

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432107T SI1592971T1 (sl) 2003-02-06 2004-02-06 Postopek za in vitro ovrednotenje stanja napredovanja okuĹľbe z virusom HIV pri posamezniku

Country Status (8)

Country Link
US (3) US20060257318A1 (sl)
EP (3) EP1445614A1 (sl)
CN (1) CN1777810A (sl)
CA (1) CA2519012C (sl)
DK (1) DK1592971T3 (sl)
ES (1) ES2435040T3 (sl)
SI (1) SI1592971T1 (sl)
WO (1) WO2004070385A1 (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method
PT2668959E (pt) * 2012-05-31 2015-02-05 Innavirvax Compostos imunogénicos compreendendo o péptido gp41 do vih acoplado à proteína transportadora crm197
WO2016181292A1 (en) 2015-05-12 2016-11-17 Piramal Enterprises Limited A process for the preparation of verapamil hydrochloride
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
CN115350181B (zh) * 2022-08-17 2023-12-29 吉林大学 一种小分子化合物在制备抗病毒感染的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401663A (en) 1981-06-30 1983-08-30 The Procter & Gamble Company Novel sulfonamide derivatives
US4443473A (en) 1981-06-30 1984-04-17 The Procter & Gamble Company Carbamate derivatives
US4424205A (en) 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL129772A0 (en) * 1996-11-06 2000-02-29 Genentech Inc Constrained helical peptides and methods of making same
WO1998030190A2 (en) 1997-01-13 1998-07-16 Sloan-Kettering Institute For Cancer Research Colon cancer kh-1 and n3 antigens
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6440663B1 (en) 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
AU783899B2 (en) * 1999-11-15 2005-12-22 Innate Pharma S.A.S. Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
WO2001055302A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
EP1328630A2 (en) * 2000-04-14 2003-07-23 Incyte Genomics, Inc. Secreted proteins
IL137419A0 (en) * 2000-07-20 2001-07-24 Yissum Res Dev Co Nk cells activating receptors and their therapeutic and diagnostic uses
EP1368478B1 (fr) 2001-01-05 2006-04-26 Sanofi Pasteur Polypeptide induisant des anticorps neutralisant le vih
WO2004016732A2 (en) * 2002-04-29 2004-02-26 The Trustees Of Columbia University In The City Of New York Astrocyte modulated genes and uses thereof

Also Published As

Publication number Publication date
CN1777810A (zh) 2006-05-24
US20060257318A1 (en) 2006-11-16
US20090117110A1 (en) 2009-05-07
EP2207034A1 (en) 2010-07-14
CA2519012C (en) 2018-10-23
EP1592971B1 (en) 2013-08-14
DK1592971T3 (da) 2013-11-11
EP2207034B1 (en) 2015-04-15
US20090136533A1 (en) 2009-05-28
US8372955B2 (en) 2013-02-12
ES2435040T3 (es) 2013-12-18
CA2519012A1 (en) 2004-08-19
WO2004070385A1 (en) 2004-08-19
EP1592971A1 (en) 2005-11-09
EP1445614A1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
HK1096540A1 (en) Methods of treating hiv infection
PL372937A1 (en) Viral antigens
GB0206359D0 (en) Viral antigens
IL177541A0 (en) A method of providing a purified, virus safe antibody preparation
AU2003248872A8 (en) Hiv integrase inhibitors
AU2003206862A1 (en) Hepatitis b vaccines
AU2003301850A8 (en) Hiv vaccine
AU2003282498A1 (en) Hiv vaccine formulations
SI1592971T1 (sl) Postopek za in vitro ovrednotenje stanja napredovanja okuĹľbe z virusom HIV pri posamezniku
AU2003205169A8 (en) Viral vaccine production method
ZA200709605B (en) HIV vaccine
GB0214494D0 (en) Vacuum flask
ZA200804099B (en) Multiclade HIV vaccines
EP1693058A4 (en) AGENT AND MEASURES FOR THE PREVENTION OF VIRAL INFECTION
AU2003235205A1 (en) Preventives for hiv infection
ZA200402741B (en) Supplements for HIV infected persons.
GB0322402D0 (en) HIV pharmaccines
GB0328686D0 (en) Plant virus
GB0129169D0 (en) Cure for HIV Aids
GB0220876D0 (en) New anti-viral/hiv/aids therapy
IL172935A0 (en) Entry inhibitors of the hiv virus
GB0314366D0 (en) High active alkyl sulphates
GB0328183D0 (en) Hygenic voice
GB0327270D0 (en) Viral replication
GB0327133D0 (en) Viral replication